TCDA - Tricida, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.46
-0.42 (-1.11%)
At close: 4:00PM EDT

37.46 0.00 (0.00%)
After hours: 4:35PM EDT

Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close37.88
Open38.60
Bid32.01 x 800
Ask65.00 x 800
Day's Range37.38 - 39.24
52 Week Range19.43 - 40.83
Volume228,795
Avg. Volume411,055
Market Cap1.841B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.00
  • Tricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript
    Motley Fool16 days ago

    Tricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript

    TCDA earnings call for the period ending March 31, 2019.

  • Business Wire16 days ago

    Tricida Announces First Quarter 2019 Financial Results

    Webcast Today at 4:30 pm Eastern Time

  • Did Hedge Funds Drop The Ball On Tricida, Inc. (TCDA) ?
    Insider Monkey22 days ago

    Did Hedge Funds Drop The Ball On Tricida, Inc. (TCDA) ?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • Business Wire24 days ago

    Tricida to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, May 8, 2019

    Tricida, Inc. (TCDA) today announced that it will report its first quarter 2019 financial results after the close of market on Wednesday, May 8, 2019. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress.

  • What Kind Of Shareholder Owns Most Tricida, Inc. (NASDAQ:TCDA) Stock?
    Simply Wall St.last month

    What Kind Of Shareholder Owns Most Tricida, Inc. (NASDAQ:TCDA) Stock?

    A look at the shareholders of Tricida, Inc. (NASDAQ:TCDA) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller compa...

  • Here's What Drove Tricida 67% Higher in March
    Motley Fool2 months ago

    Here's What Drove Tricida 67% Higher in March

    It looks like the company found an easy solution to a big problem.

  • Business Wire2 months ago

    Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Tricida, Inc. today announced the closing of its previously announced public offering of 6,440,000 shares of its common stock at a public offering price of $36.00 per share, which includes the exercise in full by the underwriters of their option to purchase 840,000 additional shares of common stock for total gross proceeds of approximately $231.8 million, before deducting underwriting discounts and ...

  • The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

  • Business Wire2 months ago

    Tricida Announces Pricing of Public Offering of Common Stock

    Tricida, Inc. today announced the pricing of its public offering of 5,600,000 shares of its common stock at a public offering price of $36.00 per share for total gross proceeds of $201.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by Tricida.

  • Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
    Zacks2 months ago

    Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

    Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

  • Why MAG Silver, comScore, and Tricida Slumped Today
    Motley Fool2 months ago

    Why MAG Silver, comScore, and Tricida Slumped Today

    Even on a great day on Wall Street, these companies couldn't share in the good news.

  • Business Wire2 months ago

    Tricida Announces Proposed Public Offering of Common Stock

    Tricida, Inc. (TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by Tricida. In addition, Tricida expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock in the offering.

  • Will Tricida Continue to Surge Higher?
    Zacks2 months ago

    Will Tricida Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Tricida.

  • TheStreet.com2 months ago

    Tricida Surges on Positive Results of Chronic Kidney Disease Treatment

    saw a surge in its stock after it produced positive results from its chronic kidney disease treatment. The stock soared about 57%, or $13.73, to close at $37.80 Thursday after results showed the company's drug TRC101, more commonly known as Veverimer, met its primary and secondary endpoints, the company said in a press release. The treatment is designed to reduce metabolic acidosis in patients affected by chronic kidney disease.

  • Here's Why Tricida's Soaring Today
    Motley Fool2 months ago

    Here's Why Tricida's Soaring Today

    Clinical trial results were a bit better than expected.

  • Tricida Inc (TCDA) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Tricida Inc (TCDA) Q4 2018 Earnings Conference Call Transcript

    TCDA earnings call for the period ending December 31, 2018.

  • Business Wire2 months ago

    Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis

    Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today results from its blinded, randomized, placebo-controlled, multicenter clinical trial, TRCA-301E, in 196 CKD patients with metabolic acidosis. TRC101 represents a first-in-class drug candidate for the treatment of metabolic acidosis, a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

  • Business Wire2 months ago

    Tricida Announces $200 Million Debt Facility With Hercules Capital

    Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has entered into an amendment to its existing debt facility with Hercules Capital, Inc. (HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets. Tricida originally entered into a $100 million debt facility with Hercules Capital in February 2018.

  • Business Wire2 months ago

    Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results

    Webcast Today at 8:00 am Eastern Time

  • ACCESSWIRE2 months ago

    Tricida Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 28, 2019 / Tricida Inc (NASDAQ: TCDA ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, 2019 at 8:00 AM Eastern ...

  • Business Wire2 months ago

    Tricida to Report Long-Term Clinical Trial Results for TRC101 in CKD Patients with Metabolic Acidosis and Host Conference Call and Webcast on Thursday, March 28, 2019

    Tricida, Inc. (TCDA) today announced that it will report results from its blinded, 40-week extension trial, TRCA-301E, tomorrow morning at 7:15 am Eastern Time. Tricida will host a conference call and webcast at 8:00 am Eastern Time to discuss the TRCA-301E clinical trial results and its financial results and other business progress.

  • Business Wire2 months ago

    Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The Lancet

    Tricida, Inc., (TCDA) a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that The Lancet published online detailed results from its Phase 3, multicenter, parallel, randomized, double-blind, placebo-controlled trial, TRCA-301, in 217 patients with CKD and metabolic acidosis. “TRC101 substantially increased blood bicarbonate levels in the TRCA-301 trial,” said Donald E. Wesson, M.D., M.B.A., Professor of Medicine at Texas A&M Health Sciences Center College of Medicine in Dallas, TX, lead investigator of the study and primary author of The Lancet paper.

  • Business Wire3 months ago

    Tricida to Report Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 28, 2019

    Tricida, Inc. (TCDA) today announced that it will report its fourth quarter and the year ended December 31, 2018 financial results at 7:00 am Eastern Time on Thursday, March 28, 2019. Tricida will host a conference call and webcast at 8:00 am Eastern Time to discuss its financial results and business progress.

  • Business Wire3 months ago

    Tricida to Present at the Cowen and Company 39th Annual Health Care Conference

    Tricida, Inc. (TCDA) today announced that it will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 8:20 am PT / 11:20 am ET. Geoff Parker, Tricida’s Chief Financial Officer, will provide a company overview, business update and progress on the company’s key initiatives. Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).

  • Business Wire4 months ago

    Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer

    Tricida, Inc. (TCDA), today announced the hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer and Senior Vice President. Dr. Cantrell will lead Tricida’s commercial planning and operations functions. “Susannah brings a breadth and depth of strategic and operational experience to Tricida that we believe will enable us to build a fine-tuned commercial organization focused on delivering a first-in-class potential therapy to not only treat metabolic acidosis but potentially slow the progression of chronic kidney disease (CKD),” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer, President and Board Member.